A new CF drug is rewriting the rulebook for the youngest patients

The TIMBERLINE phase III trial has delivered some of the most exciting results yet in cystic fibrosis (CF) treatment — and the patients are barely out of diapers. The study tested vanzacaftor-tezacaftor-deutivacaftor (VTD; Alyftrek), a triple CFTR modulator, in 67 children ages 2–5 who were already on the existing gold-standard therapy, elexacaftor-tezacaftor-ivacaftor (ETI; Trikafta). Results, presented at the European Respiratory Society Congress and published in Lancet Respiratory Medicine, showed VTD outperformed ETI in restoring chloride transport — a key marker of CF disease control.

The safety profile was reassuring: while 96% of children experienced adverse events, the vast majority were mild or moderate, and none of the serious adverse events were linked to VTD. No child discontinued treatment due to side effects. Experts are now eyeing even earlier intervention — potentially starting treatment in the first months of life or even in utero — though regulatory pathways for that don't yet exist.

By the Numbers

• Mean sweat chloride dropped from 38.4 mmol/L to 28.9 mmol/L after 24 weeks on VTD
• 92% of children achieved sweat chloride levels below the CF diagnostic threshold of 60 mmol/L
• 65% reached levels below 30 mmol/L — the greatest reduction ever recorded in any age group with any CFTR modulator
• Pulmonary exacerbation rate: 0.36 per person per year, with zero hospitalizations or IV antibiotic use

Why it matters: CF causes irreversible organ damage that begins even before birth. Getting children on more effective CFTR modulators earlier — and potentially pushing treatment into infancy or pregnancy — could prevent long-term lung and pancreatic damage that current therapies can't fully reverse once it sets in.